Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | An update on the TEMPO-2 trial: the potential of tavapadon to improve outcomes in PD

Angelo Antonini • 28 Jun 2026
EAN 2026
Movement Disorders Parkinson's Disease Tavapadon
TEMPO-2

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, gives an update on the TEMPO-2 trial (NCT04223193), which is evaluating tavapadon for early Parkinson’s disease (PD). Prof. Antonini notes that tavapadon is the first D1-receptor agonist to demonstrate improvements in mobility and functionality in both early and advanced PD. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Angelo Antonini

Advances in device-aided therapies and subcutaneous infusions for Parkinson's disease
1:26
Advances in device-aided therapies and subcutaneous infusions for Parkinson's disease
Angelo Antonini • 28 Jun 2026
The economic impact of reducing off-time and extending on-time in patients with Parkinson's disease
1:49
The economic impact of reducing off-time and extending on-time in patients with Parkinson's disease
Angelo Antonini • 22 Jun 2025
The use of blood-based biomarkers to detect Alzheimer's disease co-pathology in patients with PD
1:30
The use of blood-based biomarkers to detect Alzheimer's disease co-pathology in patients with PD
Angelo Antonini • 22 Jun 2025
Predictors of response to treatment with subcutaneous foslevodopa/foscarbidopa infusions in PD
1:09
Predictors of response to treatment with subcutaneous foslevodopa/foscarbidopa infusions in PD
Angelo Antonini • 22 Jun 2025

Related Videos

The evolving concept of synucleinopathies in the era of biomarkers
1:58
The evolving concept of synucleinopathies in the era of biomarkers
Tiago Outeiro • 28 Jun 2026
Parkinson's disease beyond motor symptoms: understanding its multisystem nature
1:15
Parkinson's disease beyond motor symptoms: understanding its multisystem nature
Tiago Outeiro • 28 Jun 2026
Advances in device-aided therapies and subcutaneous infusions for Parkinson's disease
1:26
Advances in device-aided therapies and subcutaneous infusions for Parkinson's disease
Angelo Antonini • 28 Jun 2026
Current limits of L-DOPA therapy in PD and approaches to optimization
1:19
Current limits of L-DOPA therapy in PD and approaches to optimization
Francesca Morgante • 27 Jun 2026
The content of VJNeurology is intended for healthcare professionals